Efficacy and safety of interferon beta-1b sc in older RRMS patients - A posthoc analysis of the beyond study

Journal of Neurology

Volumn 260, Issue 7, 2013, Pages 1838-1845

  Lampl, Christian ^a   Nagl, Stefan ^b   Arnason, Barry ^c   Comi, Giancarlo ^d   Oconnor, Paul ^e   Cook, Stuart ^f   Jeffery, Douglas ^g   Kappos, Ludwig ^h   Filippi, Massimo ⁱ   Beckmann, Karola ^j   Bogumil, Timon ^j   Pohl, Christoph ^j,k   Sandbrink, Rupert ^j   Hartung, Hans Peter ^l  

^a Hospital of the Sisters of Charity   (Austria)

^b SISTERS OF CHARITY HOSPITAL   (Austria)

^c UNIVERSITY OF CHICAGO   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^j BAYER PHARMA AG   (Germany)

^k UNIVERSITY HOSPITAL BONN   (Germany)

^l Department of Orthopedic Surgery   (Germany)

more..

Author keywords

Disease modifying therapy; Interferon beta 1b; Older population; RRMS

Indexed keywords

GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ADVERSE OUTCOME; AGE; ARTHRALGIA; ARTICLE; BACKACHE; CONTROLLED STUDY; DEPRESSION; DISABILITY; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INFLUENZA; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PAIN; PARESTHESIA; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; SINUSITIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VERTIGO;

ADJUVANTS, IMMUNOLOGIC; ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; TREATMENT OUTCOME;

EID: 84880265360     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6888-0     Document Type: Article

References (14)

1. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
2. Goodin DS, Frohman EM, Garmany GP et al (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169-178
3. The IFNB Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 45:1277-1285
4. Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242-1249
5. European Study Group on Interferon beta-1b in Secondary Progressive MS (1998) Placebo-controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497
6. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in remitting and relapsing multiple sclerosis: iI. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662-667
7. Barkhof F, Polman CH, Radue EW et al (2007) Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol 64:1292-1298
8. Miller DH, Molyneux PD, Barker GJ et al (1999) Effect of interferon beta-1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol 46:850-859
9. O'Connor P, Filippi M, Arnason B et al (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8:889-897
10. McDonald W, Compston A, Edan G et al (2001) Recommended diagnostic material for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
11. Lampl C, You X, Limmroth V (2012) Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age. Eur J Neurol 19:142-148
12. Simon JH, Lull J, Jacobs LD, Rudick RA et al (2000) A longitudinal study of T1 hypointense lesions in relapsing MS: mSCRG trial of interferon beta-1a multiple sclerosis collaborative research group. Neurology 55:185-192
13. Blazer D, Burchett B, Service C, George LK (1991) The association of age and depression among the elderly: an epidemiologic exploration. J Gerontol 46:210-215
14. Barin K, Dodson E (2011) Dizziness in the elderly. Otolaryngol Clin North Am 44:437-454